American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead

by admin August 2, 2025
August 2, 2025
Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead

Novo Nordisk stock sharply tanked this week, marking the pharmaceutical company’s worst-ever weekly loss with a decline of more than 30% by Friday.

This plunge extended the stock to its lowest point since August 2021, erasing nearly all gains made since the launch of its blockbuster weight-loss drug Wegovy.

Not long ago, the company was riding high, thanks to the massive success of drugs like Wegovy and Ozempic.

But now, it’s staring down a tough road. Sales projections have taken a hit, competitors are closing in, and US regulators are turning up the heat.

The sudden turn of events has rattled investors and sparked serious concerns about whether the company can hold onto its lead in an industry that’s changing fast.

Novo Nordisk stock: What’s behind the sharp drop?

On July 29, the company announced a significant revision to its full-year 2025 sales growth outlook, lowering the projected range from 13–21% to 8–14%.

Profit expectations took a hit, too. Operating income growth was revised down from 16–24% to a new range of just 10–16%.

The downgrade followed disappointing sales figures for its flagship drugs, Ozempic and Wegovy, which are increasingly feeling the pressure from growing competition, particularly in the US market.

Novo Nordisk is also struggling against growing competition from compounded or generic versions of Wegovy and competing GLP-1 drugs like Eli Lilly’s products.

The persistent use of unsafe compounded GLP-1s and counterfeit semaglutide products in the US is undermining Wegovy’s uptake.

Additionally, slower market expansion and tougher reimbursement scenarios have dampened sales growth.

These factors point to a recalibration of the obesity medication market and heightened challenges within the US, Novo Nordisk’s largest market.

Investors were already on edge when Novo Nordisk announced Maziar Mike Doustdar would take over as CEO on August 7, 2025, and the timing couldn’t have been worse.

His appointment came on the heels of a sharp cut in the company’s sales forecast, amplifying concerns and sending the stock even lower.

The leadership change follows the earlier departure of former CEO Lars Fruergaard Jørgensen, who was pushed out as doubts grew over the company’s ability to stay ahead in an increasingly competitive and fast-moving market.

What analysts say?

Analysts have a cautious view on Novo Nordisk’s stock following the company’s recent sales forecast cut and leadership change.

Bank of America downgraded the stock to “Neutral,” citing an “uncertain path to recovery for Wegovy and Ozempic” and growth headwinds from patent expiries, US pricing pressures, and competition from Eli Lilly’s drugs. 

Nordnet analysts pointed to investor panic over potential further downgrades amid US market challenges and political pressure on drug prices. 

MarketBeat data shows a consensus rating around “Hold,” with a target price near $93.67. Of 19 analysts tracked, seven recommend strong buy, nine hold, and one moderate sell.

The post Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Private equity giants accelerate push into UK pension risk-transfer market
next post
OpenAI raises $8.3B as AI demand grows: report

Related Posts

UAW union endorses Vice President Kamala Harris over...

August 2, 2024

Coinbase stock has 2 catalysts: is the CONY...

October 15, 2024

ChargePoint stock has imploded: will it rebound like...

October 4, 2024

GE Vernova stock soared to a record high:...

September 24, 2024

European stocks open lower amid Israel-Iran tensions; oil...

June 19, 2025

Boeing is in talks to reacquire fuselage maker...

March 5, 2024

Why Indonesia blocked Google Pixel sales shortly after...

November 1, 2024

From Wall Street to GOP, Trump tariffs trigger...

April 7, 2025

UK retailers warn of price hikes in 2025...

January 9, 2025

Trump wants Apple to shift iPhone production from...

May 16, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Trump moves nuclear submarines near Russia: what triggered the move and what’s ahead

      August 3, 2025
    • BOE rate cuts offer little relief as UK households face mounting financial strain

      August 3, 2025
    • Retail investors shift focus to Europe as US valuations stretch

      August 3, 2025
    • Berkshire Hathaway posts 4% dip in Q2 operating profit, writes down Kraft Heinz stake

      August 3, 2025
    • Canada ponders over retaliation costs against US tariffs

      August 3, 2025

    Categories

    • Business (3,555)
    • Investing (2,689)
    • Latest News (2,029)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved